Humacyte
HUMA0.65342.71% ( -0.0182 )
Humacyte (HUMA)
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for th...
- Open
- 0.6855
- High
- 0.6899
- Low
- 0.6441
- Prev. Close
- 0.6716
- Volume
- 1.75M
- Turnover
- 1.15M
- Avg Price
- 0.6580
- Bid/Ask Ratio
- --
- Amplitude
- 6.82%
- 52wk High
- 2.7550
- Volume Ratio
- 0.30
- Turnover Ratio
- 0.95%
Humacyte Analyst Rating
View MoreForecast & Rating
Jul 28, 2026Price forecast
$2.05213.74%
Forecast & RatingBuy
5analysts
- Strong buy60.00%
- Buy20.00%
- Hold20.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 2 days ago, 04:01 PM
Humacyte gets Nasdaq notice after shares trade below $1 bid-price minimum
- Market Beat · Jul 28 at 12:18 PM
BTIG Research Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)
- PUBT · Jul 27 at 07:03 AM
Humacyte says FDA accepts IND for first-in-human CTEV CABG study
- Global Report · Jul 22 at 04:18 AM
Supply Chain Shifts and Consumer Crosscurrents: A Look at 10 US-Listed Equities Navigating Macro Headwinds
- PUBT · Jul 14 at 07:07 AM
Humacyte names nephrologists Kossmann, Roy-Chaudhury as dialysis access advisors
- Global Report · Jul 14 at 06:47 AM
The Heterogeneity of Value Chains: From Synthetic Biology to Cloud Aggregators
